- Home
- FLX vs EYPT Comparison
FLX vs EYPT Comparison
Compare FLX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- EYPT
- Stock Information
- Founded
- FLX 2013
- EYPT 1987
- Country
- FLX China
- EYPT United States
- Employees
- FLX N/A
- EYPT N/A
- Industry
- FLX
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- FLX
- EYPT Industrials
- Exchange
- FLX NYSE
- EYPT Nasdaq
- Market Cap
- FLX 603.7M
- EYPT 594.5M
- IPO Year
- FLX 2024
- EYPT 2005
- Fundamental
- Price
- FLX $8.27
- EYPT $8.53
- Analyst Decision
- FLX
- EYPT Strong Buy
- Analyst Count
- FLX 0
- EYPT 8
- Target Price
- FLX N/A
- EYPT $25.71
- AVG Volume (30 Days)
- FLX 17.0K
- EYPT 711.5K
- Earning Date
- FLX 02-27-2025
- EYPT 03-06-2025
- Dividend Yield
- FLX N/A
- EYPT N/A
- EPS Growth
- FLX N/A
- EYPT N/A
- EPS
- FLX 0.19
- EYPT N/A
- Revenue
- FLX $663,142,775.00
- EYPT $45,713,000.00
- Revenue This Year
- FLX N/A
- EYPT N/A
- Revenue Next Year
- FLX N/A
- EYPT N/A
- P/E Ratio
- FLX $42.47
- EYPT N/A
- Revenue Growth
- FLX 1.31
- EYPT 7.50
- 52 Week Low
- FLX $6.50
- EYPT $6.90
- 52 Week High
- FLX $21.95
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- EYPT 53.88
- Support Level
- FLX N/A
- EYPT $7.15
- Resistance Level
- FLX N/A
- EYPT $9.08
- Average True Range (ATR)
- FLX 0.00
- EYPT 0.68
- MACD
- FLX 0.00
- EYPT 0.13
- Stochastic Oscillator
- FLX 0.00
- EYPT 58.72
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.